Pfizer Announces Topline PFS Survival Results From Cohort 3, Separate Randomized Cohort Of Pivotal BREAKWATER Trial, Evaluating BRAFTOVI In Combination With Cetuximab And FOLFIRI In mCRC With BRAF V600E Mutation